UY31469A1 - Nuevos hidratos de difenilazetidinona cristalinos, medicamentos que comprenden a estos compuestos y uso de los mismos - Google Patents

Nuevos hidratos de difenilazetidinona cristalinos, medicamentos que comprenden a estos compuestos y uso de los mismos

Info

Publication number
UY31469A1
UY31469A1 UY31469A UY31469A UY31469A1 UY 31469 A1 UY31469 A1 UY 31469A1 UY 31469 A UY31469 A UY 31469A UY 31469 A UY31469 A UY 31469A UY 31469 A1 UY31469 A1 UY 31469A1
Authority
UY
Uruguay
Prior art keywords
medicines
compounds
new
hydratizes
difenylazetidinone
Prior art date
Application number
UY31469A
Other languages
English (en)
Spanish (es)
Inventor
Dr Wollmann Theodor Andreas
Regina Dr Duffy
Frank Cr Cullmann
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40386121&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY31469(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of UY31469A1 publication Critical patent/UY31469A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
UY31469A 2007-11-13 2008-11-13 Nuevos hidratos de difenilazetidinona cristalinos, medicamentos que comprenden a estos compuestos y uso de los mismos UY31469A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102007063671A DE102007063671A1 (de) 2007-11-13 2007-11-13 Neue kristalline Diphenylazetidinonhydrate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE102007054497A DE102007054497B3 (de) 2007-11-13 2007-11-13 Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung

Publications (1)

Publication Number Publication Date
UY31469A1 true UY31469A1 (es) 2009-07-17

Family

ID=40386121

Family Applications (1)

Application Number Title Priority Date Filing Date
UY31469A UY31469A1 (es) 2007-11-13 2008-11-13 Nuevos hidratos de difenilazetidinona cristalinos, medicamentos que comprenden a estos compuestos y uso de los mismos

Country Status (11)

Country Link
US (1) US8003636B2 (https=)
EP (1) EP2220040B1 (https=)
JP (1) JP5401463B2 (https=)
AR (1) AR069305A1 (https=)
CL (1) CL2008003358A1 (https=)
DE (2) DE102007054497B3 (https=)
PA (1) PA8803701A1 (https=)
PE (1) PE20091165A1 (https=)
TW (1) TW200936566A (https=)
UY (1) UY31469A1 (https=)
WO (1) WO2009062619A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8486926B2 (en) * 2006-11-17 2013-07-16 Harbor Therapeutics, Inc. Steroid tetrol solid state forms
US20080319221A1 (en) * 2007-06-22 2008-12-25 Bernd Junker Esters of Pentahydroxyhexylcarbamoyl Alkanoic Acids
WO2009100258A1 (en) * 2008-02-05 2009-08-13 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical solid state forms
DK2273994T3 (en) * 2008-04-03 2016-02-01 Neurmedix Inc PHARMACEUTICAL FORMS OF A MEDICINE
WO2014094664A1 (zh) * 2012-12-22 2014-06-26 山东亨利医药科技有限责任公司 作为盐皮质激素受体拮抗剂的化合物的晶型及其制备方法
US10080759B2 (en) 2014-01-22 2018-09-25 Duke University Methods of treating pruritus
WO2015112588A1 (en) 2014-01-22 2015-07-30 Biomimetix Jv, Llc Methods of treating skin disorders

Family Cites Families (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0124317B1 (en) * 1983-04-27 1990-04-11 Ici Americas Inc. Proline derivatives
FR2663336B1 (fr) * 1990-06-18 1992-09-04 Adir Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2713225B1 (fr) 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5656624A (en) * 1994-12-21 1997-08-12 Schering Corporation 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
EP0877750B1 (en) 1995-10-31 2002-06-19 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic a gents
US6225310B1 (en) * 1996-01-17 2001-05-01 Novo Nordisk A/S Fused 1,2,4-thiadiazine derivatives, their preparation and use
EP0876379A1 (en) * 1996-01-17 1998-11-11 Novo Nordisk A/S Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
US5739321A (en) 1996-05-31 1998-04-14 Schering Corporation 3-hydroxy γ-lactone based enantionselective synthesis of azetidinones
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
US6268343B1 (en) * 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US5756470A (en) * 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
ES2199366T3 (es) 1996-12-31 2004-02-16 Dr. Reddy's Laboratories Ltd. Compuestos heterociclicos, procedimiento para su preparacion y composiciones farmaceuticas que los contienen y su uso en el tratamiento de diabetes y enfermedades relacionadas.
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
RU2215004C2 (ru) 1997-07-16 2003-10-27 Ново Нордиск А/С Конденсированное производное 1,2,4-тиадиазина, фармацевтическая композиция и способ получения лекарственного препарата
CO4970713A1 (es) * 1997-09-19 2000-11-07 Sanofi Synthelabo Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
HUP0101381A3 (en) * 1998-03-12 2002-06-28 Microbial Chem Res Found Benzofurylpyrone derivatives and pharmaceutical compositions containing them
US6221897B1 (en) 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19845405C2 (de) 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
CZ295044B6 (cs) 1998-12-07 2005-05-18 Societe De Conseils De Recherches Et D'application Analogy GLP-1, mající kyselinu aminoizomáselnou na pozicích 8 a 35, jejich použití a farmaceutické prostředky je obsahující
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
DE19916108C1 (de) 1999-04-09 2001-01-11 Aventis Pharma Gmbh Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
AR023463A1 (es) 1999-04-16 2002-09-04 Schering Corp Uso de compuestos de azetidinona
PL351470A1 (en) 1999-04-28 2003-04-22 Aventis Pharma Gmbh Tri-aryl acid derivatives as ppar receptor ligands
YU72201A (sh) 1999-04-28 2005-07-19 Aventis Pharma Deutschland Gmbh. Derivati di-aril kiseline kao ppar receptorski ligandi
GB9911863D0 (en) 1999-05-21 1999-07-21 Knoll Ag Therapeutic agents
US6399640B1 (en) 1999-06-18 2002-06-04 Merck & Co., Inc. Arylthiazolidinedione and aryloxazolidinedione derivatives
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
EP1204654B1 (en) 1999-07-29 2003-07-23 Eli Lilly And Company Benzofurylpiperazines: 5-ht2c serotonin receptor agonists
KR20020033778A (ko) 1999-09-01 2002-05-07 로버트 흐라이탁, 미쉘 베스트 설포닐 카복스아미드 유도체, 이의 제조방법 및약제로서의 이의 용도
PE20011010A1 (es) 1999-12-02 2001-10-18 Glaxo Group Ltd Oxazoles y tiazoles sustituidos como agonista del receptor activado por el proliferador de peroxisomas humano
EP1259246A2 (en) 2000-02-25 2002-11-27 Novo Nordisk A/S Use of dpp-iv inhibitors for the treatment of diabetes
ATE369337T1 (de) * 2000-04-28 2007-08-15 Asahi Kasei Pharma Corp Neue bizyklische verbindungen
ATE310728T1 (de) 2000-05-11 2005-12-15 Bristol Myers Squibb Co Tetrahydroisochinolin-analoga als wachstumshormon-sekretagoga
SE0001899D0 (sv) 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
AU7705601A (en) * 2000-07-25 2002-02-05 Merck & Co Inc N-substituted indoles useful in the treatment of diabetes
HUP0004741A2 (hu) 2000-11-28 2002-12-28 Sanofi-Synthelabo Kémiai eljárás tiazolszármazékok előállítására és új intermedier
IL156552A0 (en) * 2000-12-21 2004-01-04 Aventis Pharma Gmbh Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
MXPA03005019A (es) 2000-12-21 2003-09-25 Avantis Pharma Deutschland Gmb Derivados de difenilazetidinonas, metodo para su produccion farmacos que contienen estos compuestos y su uso.
EP1345895B1 (de) * 2000-12-21 2006-12-27 Sanofi-Aventis Deutschland GmbH Neue diphenzylazetidinone, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung zur behandlung von lipidstoffwechselstörungen
TWI291957B (en) 2001-02-23 2008-01-01 Kotobuki Pharmaceutical Co Ltd Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same
GB0113233D0 (en) 2001-05-31 2001-07-25 Glaxo Group Ltd Chemical compounds
DE10139416A1 (de) * 2001-08-17 2003-03-06 Aventis Pharma Gmbh Aminoalkyl substituierte aromatische Bicyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US6884812B2 (en) * 2001-08-31 2005-04-26 Aventis Pharma Deutschland Gmbh Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals
AU2002333456B2 (en) * 2001-08-31 2008-07-17 Sanofi-Aventis Deutschland Gmbh Diaryl cycloalkyl derivatives, method for producing the same and the use thereof as PPAR activators
IL164249A0 (en) 2002-04-11 2005-12-18 Aventis Pharma Gmbh Acyl-3-carboxphenylurea derivatives, processes forpreparing them and their use
WO2003097064A1 (en) 2002-05-17 2003-11-27 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for diabetes
US7176193B2 (en) * 2002-06-19 2007-02-13 Sanofi-Aventis Deutschland Gmbh Acid-group-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
DE10227507A1 (de) 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Kationisch substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US7671047B2 (en) * 2002-06-19 2010-03-02 Sanofi-Aventis Deutschland Gmbh Cationically substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
DE10227508A1 (de) 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Säuregruppen-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US7176194B2 (en) * 2002-06-19 2007-02-13 Sanofi-Aventis Deutschland Gmbh Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
DE10227506A1 (de) 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Ringsubstituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
GB0215579D0 (en) * 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
MXPA05000053A (es) 2002-07-12 2005-04-08 Aventis Pharma Gmbh Benzoilureas heterociclicamente sustituidas, metodo para su produccion y su uso como medicamentos.
DE10314610A1 (de) * 2003-04-01 2004-11-04 Aventis Pharma Deutschland Gmbh Neues Diphenylazetidinon mit verbesserten physiologischen Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindungen enthaltende Arzneimittel und dessen Verwendung
WO2004097655A1 (ja) 2003-04-25 2004-11-11 Matsushita Electric Industrial Co. Ltd. マルチメディア情報共有システム
JP2005015434A (ja) 2003-06-27 2005-01-20 Kotobuki Seiyaku Kk 血清コレステロール低下剤或はアテローム性硬化症の予防又は治療剤
KR20060052792A (ko) 2003-07-09 2006-05-19 포비스 메디-테크 인코포레이티드 신규 화합물 및 스테롤 및/또는 스탄올 및 콜레스테롤생합성 억제제를 포함하는 조성물 및 다양한 질병 및증상을 치료 또는 예방하기 위한 이들의 용도
WO2005005477A2 (en) 2003-07-11 2005-01-20 Novo Nordisk A/S Stabilised insulin compositions
EP1660456A2 (en) 2003-08-25 2006-05-31 Microbia Inc. Quaternary salt derivatives of 1,4-diphenylazetidin-2-ones
WO2005021497A2 (en) 2003-08-28 2005-03-10 Microbia, Inc. Tethered dimers and trimers of 1,4-diphenylazetidn-2-ones
BR122019021416A2 (https=) 2003-09-19 2019-12-21
EP1522541A1 (en) 2003-10-07 2005-04-13 Lipideon Biotechnology AG Novel hypocholesterolemic compounds
WO2005044256A1 (en) 2003-10-30 2005-05-19 Merck & Co., Inc. 2-azetidinones as anti-hypercholesterolemic agents
WO2005042692A2 (en) 2003-10-31 2005-05-12 Forbes Medi-Tech Inc. A method of inhibiting the expression of genes which mediate cellular cholesterol influx in animal cells and inhibiting the production of proteins resulting from the expression of such genes using cholesterol absorption inhibitors
ATE369335T1 (de) 2003-11-10 2007-08-15 Microbia Inc 4-biarylyl-1-phenylazetidin-2-one
AU2004308332B2 (en) 2003-12-23 2008-04-10 Merck Sharp & Dohme Corp. Anti-hypercholesterolemic compounds
GB0329778D0 (en) 2003-12-23 2004-01-28 Astrazeneca Ab Chemical compounds
ATE485267T1 (de) 2003-12-23 2010-11-15 Astrazeneca Ab Diphenylazetidinonderivate mit die cholesterinabsorption hemmender wirkung
DE602004007693T2 (de) 2004-01-06 2008-06-05 Janssen Pharmaceutica N.V. (3-oxo-3,4-dihydro-chinoxalin-2-yl-amino)-benzamid-derivate und verwandte verbindungen als glykogen-phosphorylase-hemmer zur behandlung von diabetes und adipositas
DE102004006325A1 (de) 2004-02-10 2005-08-25 Bayer Healthcare Ag Tetrahydrobenzo[d]azepin-2-on-Derivate und ihre Verwendung
SI1751131T1 (sl) 2004-03-10 2009-04-30 Janssen Pharmaceutica Nv MTP inhibirajoči aril piperidini ali piperazini substituirani s 5-členskimi heterocikli
EP1736467A4 (en) 2004-04-06 2009-07-01 Dainippon Sumitomo Pharma Co NEW SULFONIC ACID AMID DERIVATIVE
EP1734930A2 (en) 2004-04-09 2006-12-27 Smithkline Beecham Corporation Low dose pharmaceutical products
DE102004025072A1 (de) * 2004-05-21 2005-12-15 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Diphenyl-azetidinon-Derivaten
FR2871463B1 (fr) 2004-06-11 2006-09-22 Merck Sante Soc Par Actions Si Derives a structure aroyl-o-piperidine, leurs procedes de preparation, les compositions pharmaceutiques qui les contiennent et leurs applications en therapeutique
EA200700119A1 (ru) 2004-06-24 2007-10-26 Эли Лилли Энд Компани Соединения и способы лечения дислипидемии
WO2006017257A2 (en) 2004-07-12 2006-02-16 Phenomix Corporation Azetidinone derivatives
FR2873368B1 (fr) 2004-07-26 2008-01-04 Merck Sante Soc Par Actions Si Derives de guanidine et leurs utilisations en therapeutique
FR2873694B1 (fr) 2004-07-27 2006-12-08 Merck Sante Soc Par Actions Si Nouveaux aza-indoles inhibiteurs de la mtp et apob
EP1794159B1 (en) 2004-09-11 2012-08-01 Sanofi-Aventis Deutschland GmbH 7-azaindoles and their use as ppar agonists
US8030273B2 (en) 2004-10-07 2011-10-04 Novo Nordisk A/S Protracted exendin-4 compounds
WO2006037810A2 (en) 2004-10-07 2006-04-13 Novo Nordisk A/S Protracted glp-1 compounds
WO2006045564A1 (en) 2004-10-22 2006-05-04 Smithkline Beecham Corporation Xanthine derivatives with hm74a receptor activity
KR20070070231A (ko) 2004-10-22 2007-07-03 스미스클라인 비참 코포레이션 Ｈｍ７４ａ 수용체 활성을 가지는 크산틴 유도체
JPWO2006059744A1 (ja) 2004-11-30 2008-06-05 日本ケミファ株式会社 ペルオキシソーム増殖剤活性化受容体δの活性化剤
BRPI0519566A2 (pt) 2004-12-18 2009-01-27 Bayer Healthcare Ag derivados de (5s)-3-[(s)-fléor(4-trifluormetilfenil)metil]-5,6,7,8-tet raidroquinolin-5-ol e seu uso como inibidores de cetp
PE20060949A1 (es) 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
EP1838706A1 (en) 2004-12-24 2007-10-03 Prosidion Limited G-protein coupled receptor agonists
NZ556017A (en) 2004-12-24 2009-10-30 Prosidion Ltd G-protein coupled receptor (gpr116) agonists and use thereof for treating obesity and diabetes
CA2605214C (en) 2004-12-31 2016-07-12 Reddy Us Therapeutics, Inc. Benzylamine derivatives as cetp inhibitors
DE102005000666B3 (de) 2005-01-04 2006-10-05 Sanofi-Aventis Deutschland Gmbh Sulfonylpyrrolidine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AU2006210503B2 (en) 2005-02-03 2009-09-03 Irm Llc Compounds and compositions as PPAR modulators
WO2006086562A2 (en) 2005-02-09 2006-08-17 Microbia, Inc. Phenylazetidinone derivatives
FR2883000B1 (fr) 2005-03-14 2007-06-01 Merck Sante Soc Par Actions Si Derives de trifluoromethylbenzamide et leurs utilisations en therapeutique
WO2006102674A2 (en) 2005-03-24 2006-09-28 Microbia, Inc. Diphenylheterocycle cholesterol absorption inhibitors
AU2006236939A1 (en) 2005-04-13 2006-10-26 Merck Sharp & Dohme Corp. Niacin receptor agonists, compositions containing such compounds and methods of treatment
US20080194494A1 (en) 2005-04-26 2008-08-14 Microbia, Inc. 4-Biarylyl-1-Phenylazetidin-2-One Glucuronide Derivatives for Hypercholesterolemia
US20090131395A1 (en) 2005-05-05 2009-05-21 Microbia, Inc. Biphenylazetidinone cholesterol absorption inhibitors
CA2607566A1 (en) 2005-05-06 2006-11-16 Bayer Pharmaceuticals Corporation Glucagon-like peptide 1 (glp-1) receptor agonists and their pharmacological methods of use
WO2006122186A2 (en) 2005-05-10 2006-11-16 Microbia, Inc. 1,4-diphenyl-3-hydroxyalkyl-2-azetidinone derivatives for treating hypercholestrolemia
MX2007014172A (es) 2005-05-11 2008-04-02 Microbia Inc Procedimiento para la produccion de 4-bifenililacetidina-2-onas fenolicos.
CA2608311C (en) 2005-05-13 2012-11-27 Eli Lilly And Company Glp-1 pegylated compounds
US7723342B2 (en) 2005-05-17 2010-05-25 Schering Corporation Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
JP2008545700A (ja) 2005-05-25 2008-12-18 マイクロビア インコーポレーテッド ４−（ビフェニリル）アゼチジン−２−オンホスホン酸類の製造方法
US7696177B2 (en) 2005-06-15 2010-04-13 Merck Sharp & Dohme Corp. Anti-hypercholesterolemic compounds
UY29607A1 (es) 2005-06-20 2007-01-31 Astrazeneca Ab Compuestos quimicos
AR056866A1 (es) 2005-06-22 2007-10-31 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona, una formulacion farmaceutica y un proceso de preparacion del compuesto
SA06270191B1 (ar) 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
AR057383A1 (es) 2005-06-22 2007-12-05 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto
AR054482A1 (es) 2005-06-22 2007-06-27 Astrazeneca Ab Derivados de azetidinona para el tratamiento de hiperlipidemias
AR057072A1 (es) 2005-06-22 2007-11-14 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto
AR057380A1 (es) 2005-06-22 2007-11-28 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos
US7067689B1 (en) * 2005-07-08 2006-06-27 Microbia, Inc. Process for production of pentahydroxyhexylcarbamoyl alkanoic acids
JP2007022943A (ja) 2005-07-13 2007-02-01 Dai Ichi Seiyaku Co Ltd スクアレン合成酵素阻害薬
DE102005033099A1 (de) 2005-07-15 2007-01-18 Sanofi-Aventis Deutschland Gmbh Neues 1,4-Benzothiazepin-1,1-Dioxidderivat mit verbesserten Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindung enthaltende Arzneimittel und dessen Verwendung
DE102005033100B3 (de) 2005-07-15 2007-01-25 Sanofi-Aventis Deutschland Gmbh Neues 1,4-Benzothiazepin-1,1-Dioxidderivat mit verbesserten Eigenschaften, diese Verbindung enthaltene Arzneimittel und Verfahren zu deren Herstellung
WO2007015744A1 (en) 2005-07-21 2007-02-08 Incyte Corporation Disubstituted thienyl compounds and their use as pharmaceuticals
GB0516462D0 (en) 2005-08-10 2005-09-14 Smithkline Beecham Corp Novel compounds
ES2401128T3 (es) 2005-08-10 2013-04-17 Glaxosmithkline Llc Derivados de xantina como agonistas selectivos de HM74A
JP2009507791A (ja) 2005-08-29 2009-02-26 メルク エンド カムパニー インコーポレーテッド ナイアシン受容体アゴニスト、このような化合物を含有する組成物、および治療方法
WO2007026761A1 (ja) 2005-08-31 2007-03-08 Astellas Pharma Inc. チアゾール誘導体
SI1931660T1 (sl) 2005-09-29 2012-12-31 Sanofi Derivati fenil-(1,2,4)-oksadiazol-5-ona s fenilno skupino, postopki za njihovo pripravo in njihova uporaba kot zdravila
JP2009513573A (ja) 2005-09-30 2009-04-02 メルク エンド カムパニー インコーポレーテッド コレステリルエステル転送蛋白阻害剤
DE102005055726A1 (de) * 2005-11-23 2007-08-30 Sanofi-Aventis Deutschland Gmbh Hydroxy-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US20080319221A1 (en) 2007-06-22 2008-12-25 Bernd Junker Esters of Pentahydroxyhexylcarbamoyl Alkanoic Acids
US20080319218A1 (en) * 2007-06-22 2008-12-25 Andreas Haubrich Processes for Making and Using Benzyl Pentahydroxyhexylcarbamoylundecanoate
WO2009112203A1 (de) * 2008-03-14 2009-09-17 Sanofi-Aventis Deutschland Gmbh Verfahren zur herstellung eines diphenylazetidinons

Also Published As

Publication number Publication date
US8003636B2 (en) 2011-08-23
PA8803701A1 (es) 2009-06-23
EP2220040B1 (de) 2013-01-16
DE102007054497B3 (de) 2009-07-23
PE20091165A1 (es) 2009-08-31
JP2011503127A (ja) 2011-01-27
WO2009062619A1 (de) 2009-05-22
CL2008003358A1 (es) 2009-06-26
EP2220040A1 (de) 2010-08-25
TW200936566A (en) 2009-09-01
AR069305A1 (es) 2010-01-13
DE102007063671A1 (de) 2009-06-25
JP5401463B2 (ja) 2014-01-29
US20090203578A1 (en) 2009-08-13

Similar Documents

Publication Publication Date Title
ECSP11011348A (es) 2-mercaptoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3
ECSP11011390A (es) Compuestos espiro-amidas sustituidas
UY29675A1 (es) Nuevos derivados de 1,1-dióxido de 1,4-benzotiazepina con mejores propiedades, procedimiento para su preparacion, medicamentoss que comprenden este compuestoy su uso.
UY31469A1 (es) Nuevos hidratos de difenilazetidinona cristalinos, medicamentos que comprenden a estos compuestos y uso de los mismos
ECSP13012519A (es) Compuestos sustituidos de benzamida
DOP2015000264A (es) Derivados de azaadamantano y métodos de uso de los mismos
CU23515A3 (es) Nuevo proceso para la síntesis y nueva forma cristalina de agomelatina y composiciones farmacéuticas que la contienen
MX2015011311A (es) Nuevos derivados de octahidro-pirrolo[3,4-c]-pirrol y analogos del mismo como inhibidores de atotaxina.
CR20110059A (es) Compuestos organicos
EA201100037A1 (ru) Органические соединения
ATE554066T1 (de) Entzündungshemmende substituierte cyclobutendionverbindungen
CY1113716T1 (el) Νεα μεθοδος συνθεσης της αγομελατινης
CR9663A (es) Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen
UY30682A1 (es) Nueva difenilazetidinona sustituida con acido piperazina-1-sulfonico con propiedades farmacologicas mejoradas
CL2007002519A1 (es) Compuestos derivados de aminopiridina, inhibidores selectivo sobre aurora a; composicion farmaceutica que comprende a dichos compuestos; combinacion farmaceutica que comprende a dichos compuestos, utiles para inhibir el crecimiento de celulas tumoral
AR081819A1 (es) Derivados de pirimidil-piperidinil-oxipiridinona, composiciones farmaceuticas que los contienen y uso de los mismos para tratar diabetes, dislipemias, obesidad y otras enfermedades
ECSP11011346A (es) 3-Amino-2-mercaptoquinolina sustituida como modulador de KCNQ2/3
EA201690072A1 (ru) Состав, содержащий гиполипидемическое средство
CU20090064A7 (es) Nuevos derivados de benzamida como antagonistas de la bradiquinina
ECSP11011345A (es) 2-mercapto-3-aminopiridina sustituida como moduladores de kcnq2/3
PA8579901A1 (es) Bifenilcarboxamidas sustituidas con n-aril piperidina
UA110802C2 (uk) Моногідрат похідного азаадамантану
AR075418A1 (es) Polimorfo cristalino de 3-{[5-(azetidin-1-ilcarbonil)pirazin-2-il]oxi}-5-{[(1s)-1-metil-2-(metiloxi)etil]oxi}-n-(5-metilpirazin-2-il)benzamida,composiciones farmaceuticas que los contienen, proceso para prepararla y uso de las mismas para el tratamiento de la diabetes tipo ii y/u obesidad.
CY1111573T1 (el) Νεα μεθοδος συνθεσης της αγομελατινης
GT200500311A (es) Compuestos organicos

Legal Events

Date Code Title Description
DESI Application deemed to be withdrawn

Effective date: 20121119